Meros Investment Management LP Takes Position in Simulations Plus, Inc. $SLP

Meros Investment Management LP acquired a new stake in shares of Simulations Plus, Inc. (NASDAQ:SLP) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 130,229 shares of the technology company’s stock, valued at approximately $2,384,493,000.

Other large investors have also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of Simulations Plus in the 2nd quarter valued at approximately $25,000. Quarry LP bought a new stake in shares of Simulations Plus in the third quarter valued at about $28,000. GAMMA Investing LLC lifted its stake in Simulations Plus by 26.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock valued at $52,000 after acquiring an additional 585 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Simulations Plus by 59.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company’s stock worth $53,000 after buying an additional 1,669 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new stake in shares of Simulations Plus in the first quarter valued at about $54,000. Institutional investors own 78.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. William Blair downgraded shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. Wall Street Zen downgraded Simulations Plus from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Craig Hallum downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price objective on the stock. in a report on Thursday, June 18th. Finally, Weiss Ratings raised shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th. Seven investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $17.25.

Insider Activity

In related news, Director Walter S. Woltosz sold 4,177 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total transaction of $77,023.88. Following the transaction, the director owned 3,202,131 shares in the company, valued at $59,047,295.64. The trade was a 0.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.10% of the company’s stock.

Simulations Plus Stock Down 0.1%

Shares of Simulations Plus stock opened at $18.39 on Wednesday. The stock has a market cap of $372.03 million, a price-to-earnings ratio of 45.98 and a beta of 1.32. Simulations Plus, Inc. has a twelve month low of $11.09 and a twelve month high of $21.01. The company’s fifty day moving average is $18.30 and its 200 day moving average is $15.34.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Thursday, July 9th. The technology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.07. Simulations Plus had a net margin of 9.88% and a return on equity of 13.50%. The company had revenue of $21.89 million for the quarter, compared to analyst estimates of $20.90 million.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.